Sigrid Carlsson, MD, PhD; Andrew Vickers, PhD; Hans Lilja, MD, PhD; Jonas Hugosson, MD, PhD
Potential Conflicts of Interest: Dr. Lilja holds patents for free PSA, hK2, and intact PSA assays.
Carlsson S., Vickers A., Lilja H., Hugosson J.; Screening for Prostate Cancer. Ann Intern Med. 2012;156:539. doi: 10.7326/0003-4819-156-7-201204030-00014
Download citation file:
Published: Ann Intern Med. 2012;156(7):539.
TO THE EDITOR:
The U.S. Preventive Services Task Force's (USPSTF's) draft recommendation (1), which was based on Chou and colleagues' evidence review (2), gave prostate cancer screening a grade of “D” and thus concluded that “there is moderate or high certainty that [prostate cancer screening] has no net benefit or that the harms outweigh the benefits.” We sympathize with the recommendations against current screening practices in the United States; however, Chou and colleagues' review (2) contained important errors of fact, interpretation, and statistics.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only